First National Bank of Mount Dora Trust Investment Services Has $5.03 Million Position in Becton Dickinson and Co (NYSE:BDX)

First National Bank of Mount Dora Trust Investment Services boosted its holdings in Becton Dickinson and Co (NYSE:BDX) by 1.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 18,481 shares of the medical instruments supplier’s stock after acquiring an additional 275 shares during the period. Becton Dickinson and accounts for 2.1% of First National Bank of Mount Dora Trust Investment Services’ holdings, making the stock its 15th biggest position. First National Bank of Mount Dora Trust Investment Services’ holdings in Becton Dickinson and were worth $5,026,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in BDX. Wealthfront Advisers LLC grew its position in shares of Becton Dickinson and by 0.6% in the 4th quarter. Wealthfront Advisers LLC now owns 6,178 shares of the medical instruments supplier’s stock valued at $1,680,000 after buying an additional 37 shares during the last quarter. Mountain Pacific Investment Advisers Inc. ID boosted its position in Becton Dickinson and by 0.6% during the fourth quarter. Mountain Pacific Investment Advisers Inc. ID now owns 6,368 shares of the medical instruments supplier’s stock valued at $1,732,000 after acquiring an additional 40 shares during the last quarter. Duncker Streett & Co. Inc. grew its holdings in Becton Dickinson and by 0.4% during the 3rd quarter. Duncker Streett & Co. Inc. now owns 9,948 shares of the medical instruments supplier’s stock worth $2,517,000 after acquiring an additional 44 shares during the period. Northwestern Mutual Investment Management Company LLC grew its holdings in Becton Dickinson and by 0.5% during the 3rd quarter. Northwestern Mutual Investment Management Company LLC now owns 10,280 shares of the medical instruments supplier’s stock worth $2,600,000 after acquiring an additional 49 shares during the period. Finally, West Oak Capital LLC boosted its position in shares of Becton Dickinson and by 2.6% during the 3rd quarter. West Oak Capital LLC now owns 1,996 shares of the medical instruments supplier’s stock valued at $505,000 after purchasing an additional 50 shares in the last quarter. 84.49% of the stock is owned by institutional investors and hedge funds.

Shares of Becton Dickinson and stock traded down $1.22 on Friday, reaching $278.28. 68,352 shares of the stock were exchanged, compared to its average volume of 998,215. The business has a 50 day moving average price of $270.98 and a two-hundred day moving average price of $257.07. The firm has a market capitalization of $75.41 billion, a price-to-earnings ratio of 71.41, a PEG ratio of 1.99 and a beta of 1.07. The company has a quick ratio of 0.72, a current ratio of 1.18 and a debt-to-equity ratio of 0.86. Becton Dickinson and Co has a twelve month low of $221.47 and a twelve month high of $280.29.

Becton Dickinson and (NYSE:BDX) last released its quarterly earnings results on Tuesday, November 5th. The medical instruments supplier reported $3.31 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.30 by $0.01. The company had revenue of $4.58 billion for the quarter, compared to analyst estimates of $4.57 billion. Becton Dickinson and had a net margin of 6.84% and a return on equity of 15.52%. The firm’s revenue was up 4.1% on a year-over-year basis. During the same quarter last year, the business earned $2.93 earnings per share. Research analysts forecast that Becton Dickinson and Co will post 12.57 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, December 31st. Shareholders of record on Tuesday, December 10th were issued a $0.79 dividend. This is an increase from Becton Dickinson and’s previous quarterly dividend of $0.77. The ex-dividend date of this dividend was Monday, December 9th. This represents a $3.16 dividend on an annualized basis and a yield of 1.14%. Becton Dickinson and’s dividend payout ratio is presently 27.05%.

A number of equities research analysts have weighed in on the company. KeyCorp lifted their target price on Becton Dickinson and from $284.00 to $298.00 and gave the stock an “overweight” rating in a report on Wednesday. Morgan Stanley upped their target price on shares of Becton Dickinson and from $261.00 to $287.00 and gave the stock an “equal weight” rating in a research note on Tuesday, December 17th. Barclays downgraded Becton Dickinson and from an “overweight” rating to an “equal weight” rating and set a $275.00 price objective for the company. in a research note on Wednesday, January 8th. JPMorgan Chase & Co. raised their target price on Becton Dickinson and from $285.00 to $300.00 and gave the stock an “overweight” rating in a research report on Friday, December 20th. Finally, Stifel Nicolaus lifted their target price on Becton Dickinson and from $275.00 to $295.00 and gave the company a “buy” rating in a report on Monday, December 16th. Six equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $281.90.

In other Becton Dickinson and news, CEO Vincent A. Forlenza sold 13,860 shares of the firm’s stock in a transaction that occurred on Wednesday, January 8th. The shares were sold at an average price of $275.19, for a total value of $3,814,133.40. Following the completion of the transaction, the chief executive officer now owns 227,647 shares of the company’s stock, valued at approximately $62,646,177.93. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Vincent A. Forlenza sold 11,626 shares of the business’s stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $265.57, for a total value of $3,087,516.82. Following the transaction, the chief executive officer now directly owns 225,393 shares of the company’s stock, valued at $59,857,619.01. The disclosure for this sale can be found here. In the last quarter, insiders have sold 91,231 shares of company stock worth $24,787,690. 0.12% of the stock is currently owned by company insiders.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

See Also: How to Trade Using Analysts Ratings

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.